Morgan Stanley Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $34
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Overweight rating and announces Price Target of $34.
Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Overweight rating and announces Price Target of $34.